<DOC>
	<DOCNO>NCT01321775</DOCNO>
	<brief_summary>The purpose study determine efficacy combine therapy Bevacizumab , trastuzumab paclitaxel neo-adjuvant therapy patient breast cancer HER 2+ follow surgery adjuvant therapy ( Cyclophosphamide , Trastuzumab Doxorubicin liposomal ) .</brief_summary>
	<brief_title>Bevacizumab Trastuzumab With Weekly Paclitaxel Followed , After Surgery , Encapsuled Liposomal Doxorubicin , Cyclophosphamide Trastuzumab Adjuvant Treatment After Surgery Women With Her2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Older 18 year Pre post menopause patient histology confirmation breast cancer status II III , Her2+ confirm FISH technique . Lesion big 2cm . life expectancy &gt; 12 week . Normal Heart function ( LVEF &gt; 55 % ) Patient give his/her sign , write informed consent . Previous chemotherapy treatment . Previous treatment HER2 VEGF inhibitor . Pulmonary disease control . Hypertension control ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) significant cardiovascular disease ( CVA/cerebral hemorrhage ( 6 month inclusion ) , myocardial infarction ( 6 month inclusion ) , unstable angina , congestive cardiac disease â‰¥ NYHA 2 , serious cardiac arrhythmia require medication . Antecedents coagulopathy clinically significant thrombosis . Major surgery , open biopsy significant trauma 28 day inclusion study plan major surgery study . Peripheral Neuropathy &gt; CTC 2 inclusion . Altered renal function a. Creatinine &gt; 2.0 mg/dL 177 mmol/L . b.Proteinuria &gt; 2+ reactive stick ( dipstick ) . If screen proteinuria 2+ , collection 24h urine must show value proteins 1 g/24h . Daily chronic treatment corticosteroid Daily chronic treatment aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) Antecedents heritage evidence bleeder diathesis coagulopathy risk hemorrhage . Antecedents abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month previous inclusion . Active infection treat iv antibiotic Serious injury curing , peptic ulcer bone fracture . Pregnant active sexual patient use contraceptive method . lactate woman Current recent treatment another IMP participation another clinical trial ( 30 day inclusion ) Another primary tumor ( include primary brain tumor ) within 5 year study inclusion , apart situ cervix carcinoma , skin squamous carcinoma , appropriately treat , skin basal cell cancer control .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>